179 related articles for article (PubMed ID: 32162214)
1. Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions.
Makino K; Mahant N; Tilden D; Aghajanian L
Neurol Ther; 2020 Jun; 9(1):117-133. PubMed ID: 32162214
[TBL] [Abstract][Full Text] [Related]
2. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Dorsch U; Csikós J; Blitzer A
Parkinsonism Relat Disord; 2020 Jan; 70():23-30. PubMed ID: 31794936
[TBL] [Abstract][Full Text] [Related]
3. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients.
Jost WH; Steffen A; Berweck S
Expert Rev Neurother; 2021 Oct; 21(10):1059-1068. PubMed ID: 34516331
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
6. Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis.
Berweck S; Banach M; Gaebler-Spira D; Chambers HG; Schroeder AS; Geister TL; Althaus M; Hanschmann A; Vacchelli M; Bonfert MV; Heinen F; Dabrowski E
Toxins (Basel); 2022 Aug; 14(9):. PubMed ID: 36136523
[TBL] [Abstract][Full Text] [Related]
7. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Csikós J; Cairney CJ; Blitzer A
Neurology; 2019 Apr; 92(17):e1982-e1991. PubMed ID: 30918101
[TBL] [Abstract][Full Text] [Related]
8. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
[TBL] [Abstract][Full Text] [Related]
9. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
[TBL] [Abstract][Full Text] [Related]
10. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
Shaw L; Rodgers H; Price C; van Wijck F; Shackley P; Steen N; Barnes M; Ford G; Graham L;
Health Technol Assess; 2010 May; 14(26):1-113, iii-iv. PubMed ID: 20515600
[TBL] [Abstract][Full Text] [Related]
11. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E; Ellis C; Brassington R; Sathasivam S; Young CA
Cochrane Database Syst Rev; 2022 May; 5(5):CD006981. PubMed ID: 35593746
[TBL] [Abstract][Full Text] [Related]
12. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
Kazerooni R; Watanabe JH
J Manag Care Spec Pharm; 2021 Apr; 27(4):478-487. PubMed ID: 33511895
[No Abstract] [Full Text] [Related]
13. The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a systematic review and meta-analysis.
Yang CL; Huang JP; Tan YC; Wang TT; Zhang H; Qu Y
BMC Pharmacol Toxicol; 2023 Oct; 24(1):52. PubMed ID: 37828600
[TBL] [Abstract][Full Text] [Related]
14. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins.
Lakraj AA; Moghimi N; Jabbari B
Toxins (Basel); 2013 May; 5(5):1010-31. PubMed ID: 23698357
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Cost Analysis of Patients Who Switched from OnabotulinumtoxinA to IncobotulinumtoxinA in a Private Neurology Practice.
Karschney VK; Greeley DR
Am Health Drug Benefits; 2020; 13(5):205-210. PubMed ID: 33343821
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective.
Makino K; Tilden D; Guarnieri C; Mudge M; Baguley IJ
Pharmacoecon Open; 2019 Mar; 3(1):93-102. PubMed ID: 29915932
[TBL] [Abstract][Full Text] [Related]
18. Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.
Berweck S; Bonikowski M; Kim H; Althaus M; Flatau-Baqué B; Mueller D; Banach MD
Neurology; 2021 Oct; 97(14):e1425-e1436. PubMed ID: 34341153
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.
Salcedo J; Bulovic J; Young CM
Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408
[TBL] [Abstract][Full Text] [Related]
20. Therapy of Sialorrhea with Botulinum Neurotoxin.
Jost WH; Bäumer T; Laskawi R; Slawek J; Spittau B; Steffen A; Winterholler M; Bavikatte G
Neurol Ther; 2019 Dec; 8(2):273-288. PubMed ID: 31542879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
